CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...